ES2515715T3 - Formulaciones de pancreolipasa de baja potencia con recubrimiento entérico - Google Patents

Formulaciones de pancreolipasa de baja potencia con recubrimiento entérico Download PDF

Info

Publication number
ES2515715T3
ES2515715T3 ES11788223.3T ES11788223T ES2515715T3 ES 2515715 T3 ES2515715 T3 ES 2515715T3 ES 11788223 T ES11788223 T ES 11788223T ES 2515715 T3 ES2515715 T3 ES 2515715T3
Authority
ES
Spain
Prior art keywords
rsd
usp
time
pancreolipase
microcrystalline cellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11788223.3T
Other languages
English (en)
Other versions
ES2515715T5 (es
Inventor
Giovanni Ortenzi
Giuseppe De Franza
Danilo Clementi
Christian Stollberg
Luigi Boltri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Pharmaceuticals Holdings Ireland ULC
Original Assignee
Aptalis Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45044628&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2515715(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aptalis Pharma Ltd filed Critical Aptalis Pharma Ltd
Publication of ES2515715T3 publication Critical patent/ES2515715T3/es
Application granted granted Critical
Publication of ES2515715T5 publication Critical patent/ES2515715T5/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composición que contiene al menos una enzima digestiva y al menos un portador en la que: a) la cantidad total de enzimas digestivas en la composición es entre aproximadamente 4 y aproximadamente 20% en peso, donde el portador se elige del grupo que consiste en polioles, azúcares, alcoholes de azúcar, celulosa, sales de fosfato de calcio, aminoácidos y sus mezclas; y al menos un portador de la composición tiene un tamaño de partícula mayor de 100 μm.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
E11788223
13-10-2014
midiendo la densidad (tanto la aparente como la de compactación), el índice Carr (índice de compactabilidad), la fluidez (velocidad de flujo a través de un orificio se mide como la masa por tiempo que fluye desde un embudo, método USP) y la PPS. El resumen de los resultados se muestra en la Tabla 4.
Tabla 4.
Lote
Densidad % Índice Carr Flujo de masa g/s (100 g) PPS %
No compactada
Compactada Ø 10 mm g/s Ø 15 mm g/s Ø 20 mm g/s Ø 30 mm g/s T = 0 24 h/ temp. amb; vial cerrado 24 h/ temp. amb; vial abierto 72 h/ temp. amb; vial cerrado 72 h/ temp. amb; vial abierto
Muestra de referenciaA
0.657 0.781 15.88 7.1 / / / 0.96 1.51 2.69 / /
Celulosa microcristalina C3
0.438 0.561 21.93 Sin flujo Sin flujo Sin flujo 20.8 3.68 4.05 4.04 / /
Celulosa microcristalina B2
0.423 0.500 15.40 10.4 / / / 1.09 1.59 2.12 / /
Trehalosa G
0.757 0.892 15.13 5.9 / / / 6.45 6.7 2 6.52 / /
Lactosa monohidratada
0.549 0.632 13.13 7.1 / / / 0.43 0.71 0.87 / /
L-Prolina
0.512 0.581 11.88 4.5 / / / 0.43 / / 0.52 0.97
Calcio bibásico
0.694 0.806 13.90 9.1 / / / 0.70 / / 0.89 1.25
Isomalt
0.434 0.500 13.20 5.5 / / / 2.55 / / 2.57 2.84
Lactosa Anhidra
0.769 0.833 7.68 4.34 / / / 0.43 / / 0.51 0.86
Celulosa microcristalina A1
0.434 0.515 15.73 4.34 / / / 3.89 3.92 3.96 / /
Inositol
0.609 0.781 22.02 6.66 / / / 0.61 / / 0.45 0.93
Mezclas de celulosa microcristalina B2 +C3 (1:1)
0.442 0.549 19.49 Sin flujo 5.88 / / 2.72 2.8 2.91 / /
Celulosa microcristalina A1 + C3 (1:1)
0.454 0.568 20.07 Sin flujo 14.28 / / 3.36 4.17 4.17 / /
Celulosa microcristalina C3 + trehalosa G (1:1)
0.561 0.724 22.51 Sin flujo 8.33 / / 2.78 5.64 5.86 / /
Celulosa microcristalina C3 + L-prolina (1:1)
0.515 0.649 20.65 Sin flujo 12.5 / / 2.39 2.19 2.18 / /
Celulosa microcristalina C3 + lactosa anhidra (1:1)
0.555 0.684 18.86 Sin flujo 3.33 / / 2.07 2.27 2.15 / /
15
E11788223
13-10-2014
Lote
Densidad % Índice Carr Flujo de masa g/s (100 g) PPS %
No compactada
Compactada Ø 10 mm g/s Ø 15 mm g/s Ø 20 mm g/s Ø 30 mm g/s T = 0 24 h/ temp. amb; vial cerrado 24 h/ temp. amb; vial abierto 72 h/ temp. amb; vial cerrado 72 h/ temp. amb; vial abierto
Celulosa microcristalina C3 + lactosa monohidratada (1:1)
0.521 0.657 20.70 Sin flujo 10.0 / / 1.94 2.18 2.36 / /
Celulosa microcristalina C3 + calcio bibásico (1:1)
0.561 0.704 20.31 Sin flujo 10.5 / / 2.1 2.5 2.65 /
Celulosa microcristalina C3 + Isomalt (1:1)
0.510 0.609 16.26 Sin flujo 12.5 / / 3.38 3.37 3.4 / /
Celulosa microcristalina C3 + Inositol (1:1)
0.531 0.675 21.33 Sin flujo 6.66 / / 2.29 / / 2.06 2.27
A Muestra de referencia: pancreolipasa (90%), croscarmelosa sódica (3.0%), aceite de ricino hidrogenado (1.0%), dióxido de silicio coloidal (0.5%), celulosa microcristalina (5%) (Avicel® PH101); estearato de magnesio (0.5%)
Tabla 5. Tipos de celulosas microcristalinas
imagen14
Tamaño medio nominal de partícula (µm) Análisis del tamaño de partícula: PPS
imagen15
Tamaño de malla Cantidad retenida %
1Celulosa microcristalina A
160 38 ≤1 <5%
94
≤ 50
imagen16
imagen17 300 ≤ 70
2Celulosa microcristalina B
180 60 ≥ 10.0 <5%
100
≥ 50
3Celulosa microcristalina C
50 60 ≤ 1 <5%
200
≤ 30
La celulosa cristalina A se comercializa como Vivapure®12; la celulosa cristalina B se comercializa como Avicel® 5 LM200; la celulosa cristalina C se comercializa como Avicel® PH101.
De la tabla 4 anterior se evidencia que la celulosa microcristalina C (contenido de humedad menor o igual de 5%, tamaño medio nominal de partícula de 50 µm, tamaño de malla 60: cantidad retenida ≤1.0%, tamaño de malla 200: cantidad retenida ≤ 30.0%) tiene un flujo de masa bajo que es una indicación de problemas críticos durante el
10 proceso de compresión directa. Para evitar dichos problemas con portadores que tienen baja fluidez, se debería llevar a cabo un paso de tratamiento adicional (como granulación húmeda) para aumentar el flujo de masa. Sin embargo, cualquiera de dichos pasos adicionales son perjudiciales para la actividad enzimática de la formulación de pancreolipasa y por consiguiente se deben evitar para reducir el riesgo de degradación.
15 Ejemplo 3. Mediciones de la dureza de los comprimidos de las mezclas de pancreolipasa - portador
La materia prima pancreolipasa (p. ej, recibida de Nordmark) se mezcla con diferentes portadores para formar las siete mezclas distintas: mezcla 1: pancreolipasa; mezcla 2: pancreolipasa y celulosa microcristalina B; mezcla 3: pancreolipasa y trehalosa; mezcla 4: pancreolipasa e isomalt; mezcla 5: pancreolipasa y calcio bibásico; mezcla 6:
16
imagen18
imagen19
imagen20
E11788223
13-10-2014

Tabla 12. Estabilidad de microcomprimidos a granel de pancreolipasa diluida con recubrimiento entérico (µC); condiciones de almacenamiento: 40 °C + 75% de humedad relativa
imagen21
Actividad de lipasa unidades USP/mg
Lote
Tiempo 0 Tiempo 3 mo Dif. tiempo
µC1 (portador: celulosa microcristalina A)
11.5 11.2 97
µC2 (portador: celulosa microcristalina A y trehalosa)
11.7 11.7 100
µC3 (portador: celulosa microcristalina B y trehalosa)
11.5 11.4 99
Tabla 13. Análisis de microcomprimidos de pancreolipasa diluida con recubrimiento entérico, µC1 (portador: celulosa microcristalina A); condiciones de almacenamiento: 25 °C, 60% de humedad relativa
Prueba
Especificación Tiempo 0 Tiempo 1 mo Tiempo 2 mo Tiempo 3 mo
Aspecto
Perlas livianas pequeñas marrones corresp corresp corresp corresp
Actividad de lipasa (unidades USP/cps)
90-110% de lo declarado en la rotulación 735 761 754 774
675-825 unidades USP/cps
% declarado en la rotulación
98 101 101 103
Dff T0 (%)
104 103 105
Actividad de proteasa (unidades USP/cps)
1250-3850 unidades USP/cps 2015 2145 2145 2210
Actividad de amilasa (unidades USP/cps)
1600-6575 unidades USP/cps 2600 2665 2665 2795
Ácido ftálico (%)
NMT 1.4% 0.1 0.1 0.1 0.1
PPS(%)
NMT 5.0% 2.4 0.5 0.1 0.3
Disolución (%)
NLT 75% 30 min 84% (RSD 3.6) 87% (RSD 2.6) 85% (RSD 2.1) 83% (RSD 3.0)
Disolución (%) x 1.125
95% (RSD 2.9) 98% (RSD 2.2) 96% (RSD 1.5) 94% (RSD 3.0)
Peso n = 10 (mg)
imagen22 65 65 65 65

Tabla 14. Análisis de microcomprimidos de pancreolipasa diluida con recubrimiento entérico, µC1 (portador: celulosa microcristalina A); condiciones de almacenamiento: 40 °C, 75% de humedad relativa
Prueba
Especificación Tiempo 0 Tiempo 1 mo Tiempo 2 mo Tiempo 3 mo
Aspecto
Perlas livianas pequeñas marrones corresp corresp corresp corresp
Actividad de lipasa (unidades USP/cps)
90-110% de lo declarado en la rotulación 735 754 754 754
675-825 unidades USP/cps
% declarado en la rotulación
98 101 101 101
Dff T0 (%)
103 103 103
Actividad de proteasa (unidades
1250-3850 unidades USP/cps 2015 2080 2015 2015
USP/cps
imagen23
20
E11788223
13-10-2014
Prueba
Especificación Tiempo 0 Tiempo 1 mo Tiempo 2 mo Tiempo 3 mo
Actividad de amilasa (unidades USP/cps)
1600-6575 unidades USP/cps 2600 2665 2600 2795
Ácido ftálico (%)
NMT 1.4% 0.1 0.1 0.1 0.1
PPS(%)
NMT 5.0% 2.4 0.4 0.1 0.2
Disolución (%)
NLT 75% 30 min 84% (RSD 3.6) 84% (RSD 2.9) 83% (RSD 2.2) 82% RD 1.8)
Disolución (%) x 1.125
imagen24 95% (RSD 2.9) 94% (RSD 2.2) 96% (RSD 2.3) 93% (RSD 1.8)
Peso n = 10 (mg)
imagen25 65 65 65 65

Tabla 15. Análisis de microcomprimidos de pancreolipasa diluida con recubrimiento entérico, µC2 (portador: celulosa microcristalina A y trehalosa); condiciones de almacenamiento: 25 °C, 76% de humedad relativa
Prueba
Especificación Tiempo 0 Tiempo 1 mo Tiempo 2 mo Tiempo 3 mo
Aspecto
Perlas livianas pequeñas marrones corresp corresp corresp corresp
Actividad de lipasa (unidades USP/cps)
90-110% de lo declarado en la rotulación 736 755 762 755
675-825 unidades USP/cps
imagen26 imagen27 imagen28
% declarado en la rotulación
98 101 102 101
Dff T0 (%)
imagen29 103 104 103
Actividad de proteasa (unidades USP/cps)
1250-3850 unidades USP/cps 1984 2048 1984 2112
Actividad de amilasa (unidades USP/cps)
1600-6575 U USP/cps 2496 2688 2880 2816
Ácido ftálico (%)
NMT 1.4% 0.1 0.1 0.1 0.1
PPS(%)
NMT 5.0% 1.6 0.2 0.2 0.3
Disolución (%)
NLT 75% 30 min 84% (RSD 2.0) 91% (RSD 3.6) 87% (RSD 2.4) 86% RD 12.2)
Disolución (%) x 1.125
imagen30 94% (RSD 2.3) 103% (RSD 3.6) 98% (RSD 2.5) 96% (RSD 1.7)
Peso n = 10 (mg)
imagen31 64 64 64 64

Tabla 16. Análisis de microcomprimidos de pancreolipasa diluida con recubrimiento entérico, µC2 (portador: celulosa microcristalina A y trehalosa); condiciones de almacenamiento: 40 °C, 75% de humedad relativa
Prueba
Especificación Tiempo 0 Tiempo 1 mo Tiempo 2 mo Tiempo 3 mo
Aspecto
Perlas livianas pequeñas marrones corresp corresp corresp corresp
Actividad de lipasa (unidades USP/cps)
90-110% de lo declarado en la rotulación 736 755 781 742
imagen32
675-825 unidades USP/cps imagen33 imagen34 imagen35
imagen36
% declarado en la rotulación 98 101 104 199
imagen37
Dff T0 (%) imagen38 103 106 101
Actividad de proteasa (unidades USP/cps)
1250-3850 unidades USP/cps 1984 2240 2048 1984
21
E11788223
13-10-2014
Prueba
Especificación Tiempo 0 Tiempo 1 mo Tiempo 2 mo Tiempo 3 mo
Actividad de amilasa (unidades USP/cps)
1600-6575 unidades USP/cps 2496 2688 2880 2688
Ácido ftálico (%)
NMT 1.4% 0.1 0.1 0.1 0.1
PPS(%)
NMT 5.0% 1.6 0.5 0.2 0.3
Disolución (%)
NLT 75% 30 min 84% (RSD 2.0) 91% (RSD 2.6) 87% (RSD 3.7) 84% RD 1.4)
Disolución (%) x 1.125
imagen39 94% (RSD 2.3) 103% (RSD 2.7) 98% (RSD 4.0) 94% (RSD 1.7)
Peso n = 10 (mg)
imagen40 64 64 64 64

Tabla 17. Análisis de microcomprimidos de pancreolipasa diluida con recubrimiento entérico, µC3 (portador: celulosa microcristalina B y trehalosa); condiciones de almacenamiento: 25 °C, 60% de humedad relativa
Prueba
Especificación Tiempo 0 Tiempo 1 mo Tiempo 2 mo Tiempo 3 mo
Aspecto
Perlas livianas pequeñas marrones corresp corresp corresp corresp
Actividad de lipasa (unidades USP/cps)
90-110% de lo declarado en la rotulación 746 770 779 792
675-825 unidades USP/cps
imagen41 imagen42 imagen43
% declarado en la rotulación
99 104 104 106
Dff T0 (%)
imagen44 104 104 106
Actividad de proteasa (unidades USP/cps)
1250-3850 unidades USP/cps 1980 2112 2112 2112
Actividad de amilasa (unidades USP/cps)
1600-6575 unidades USP/cps 2640 2838 2772 2838
Ácido Ftáltico (%)
NMT 1.4% 0.1 0.1 0.1 0.1
PPS(%)
NMT 5.0% 1.6 0.5 0.2 0.3
Disolución (%)
NLT 75% 30 min 87% (RSD 2.4) 91% (RSD 2.6) 89% (RSD 1.4) 91% RD 3.4)
Disolución (%) x 1.125
imagen45 98% (RSD 2.1) 102% (RSD 2.7) 100% (RSD 1.2) 103% (RSD 3.4)
Peso n = 10 (mg)
imagen46 66 66 66 66

Tabla 18. Análisis de microcomprimidos de pancreolipasa diluida con recubrimiento entérico, µC3 (portador: celulosa microcristalina B y trehalosa); condiciones de almacenamiento: 40 °C, 75% de humedad relativa
Prueba
Especificación Tiempo 0 Tiempo 1 mo Tiempo 2 mo Tiempo 3 mo
Aspecto
Perlas livianas pequeñas marrones corresp corresp corresp corresp
Actividad de lipasa (unidades USP/cps)
90-110% de lo declarado en la rotulación 746 766 766 766
imagen47
675-825 unidades USP/cps imagen48 imagen49 imagen50
imagen51
% declarado en la rotulación 99 102 102 102
imagen52
Dif T0 (%) imagen53 103 103 103
Actividad de proteasa (unidades USP/cps)
1250-3850 unidades USP/cps 1980 1980 2046 2046
22
imagen54

Claims (1)

  1. imagen1
    imagen2
ES11788223T 2010-10-01 2011-09-30 Formulaciones de pancreolipasa de baja potencia con recubrimiento entérico Active ES2515715T5 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38903710P 2010-10-01 2010-10-01
US389037P 2010-10-01
PCT/IB2011/002419 WO2012042372A1 (en) 2010-10-01 2011-09-30 Enteric coated, low- strength pancrelipase formulations

Publications (2)

Publication Number Publication Date
ES2515715T3 true ES2515715T3 (es) 2014-10-30
ES2515715T5 ES2515715T5 (es) 2021-06-22

Family

ID=45044628

Family Applications (2)

Application Number Title Priority Date Filing Date
ES11788223T Active ES2515715T5 (es) 2010-10-01 2011-09-30 Formulaciones de pancreolipasa de baja potencia con recubrimiento entérico
ES14176579.2T Active ES2657673T3 (es) 2010-10-01 2011-09-30 Formulaciones recubiertas entéricas de pancrelipasa, de baja intensidad

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES14176579.2T Active ES2657673T3 (es) 2010-10-01 2011-09-30 Formulaciones recubiertas entéricas de pancrelipasa, de baja intensidad

Country Status (26)

Country Link
US (2) US11364205B2 (es)
EP (2) EP2621476B8 (es)
JP (2) JP6043929B2 (es)
KR (2) KR101968457B1 (es)
CN (2) CN108187033A (es)
AR (1) AR093181A1 (es)
AU (2) AU2011309763B2 (es)
BR (1) BR112013007640A2 (es)
CA (1) CA2812862C (es)
CL (1) CL2011002432A1 (es)
CO (1) CO6700848A2 (es)
DK (1) DK2621476T4 (es)
EA (3) EA030450B1 (es)
ES (2) ES2515715T5 (es)
HR (1) HRP20140995T1 (es)
IL (1) IL225504A (es)
MX (1) MX348118B (es)
PL (1) PL2621476T5 (es)
PT (1) PT2621476E (es)
RS (1) RS53587B1 (es)
SA (1) SA111320804B1 (es)
SI (1) SI2621476T1 (es)
SM (1) SMT201400149B (es)
UA (1) UA111726C2 (es)
WO (1) WO2012042372A1 (es)
ZA (1) ZA201303087B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) * 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
SG186648A1 (en) 2007-02-20 2013-01-30 Aptalis Pharma Ltd Stable digestive enzyme compositions
US10087493B2 (en) 2008-03-07 2018-10-02 Aptalis Pharma Canada Ulc Method for detecting infectious parvovirus in pharmaceutical preparations
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
PL2318035T3 (pl) 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
WO2010080835A1 (en) 2009-01-06 2010-07-15 Curemark Llc Compositions and methods for the treatment or the prevention oral infections by e. coli
KR20170005192A (ko) 2009-01-06 2017-01-11 큐어론 엘엘씨 스타필로코쿠스 아우레우스 감염의 치료 또는 예방 및 표면 상의 스타필로코쿠스 아우레우스의 박멸 또는 감소를 위한 조성물 및 방법
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
WO2011050135A1 (en) 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
JP6043929B2 (ja) 2010-10-01 2016-12-14 アラガン ファーマシューティカルズ インターナショナル リミテッド 腸溶コーティングされた低力価パンクレリパーゼ製剤
BR112013027034A8 (pt) 2011-04-21 2018-01-02 Curemark Llc "compostos para o tratamento de transtornos neuropsiquiátricos."
EP2987499B1 (en) 2011-08-08 2019-05-08 Allergan Pharmaceuticals International Limited Method for dissolution testing of solid compositions containing digestive enzymes
US10350278B2 (en) * 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
AU2014229330B2 (en) 2013-03-15 2018-08-09 Allergan Pharmaceuticals International Limited Composition containing digestive enzymes and nutrients suitable for enteral administration
US10184121B2 (en) 2013-06-28 2019-01-22 Allergan Pharmaceuticals International Limited Methods for removing viral contaminants from pancreatic extracts
JP2016537387A (ja) * 2013-08-09 2016-12-01 アラガン ファーマシューティカルズ インターナショナル リミテッド 経腸投与に適した消化酵素組成物
CN106659773A (zh) * 2013-11-05 2017-05-10 阿勒根制药国际有限公司 高效的胰酶药物组合物
JP6442659B1 (ja) * 2017-12-28 2018-12-26 株式会社フクハラ 細菌増殖警報器付き除菌フィルタ
WO2020257802A1 (en) * 2019-06-21 2020-12-24 Das Aditya Spray dried oral pharmaceutical compositions for enteric hepatic or intestinal delivery
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2751330A (en) 1952-08-27 1956-06-19 Armour & Co Use of a salt in the extraction slurry in recovering proteolytic enzymes from pancreas gland material
FR1484458A (es) 1965-06-25 1967-09-15
GB1342409A (en) 1970-07-23 1974-01-03 Ciba Geigy Ag Flowable pancreatin preparation of low microorgan ism content and a process for its manufacture
DE2460334C3 (de) 1974-12-20 1979-09-06 Hoechst Ag, 6000 Frankfurt Verfahren zur Gewinnung von Insulin und Pankreatin aus Schweinepankreas
GB1509866A (en) 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
US4237229A (en) 1975-06-10 1980-12-02 W. R. Grace & Co. Immobilization of biological material with polyurethane polymers
GB1590432A (en) † 1976-07-07 1981-06-03 Novo Industri As Process for the production of an enzyme granulate and the enzyme granuate thus produced
JPS5535031A (en) 1978-09-04 1980-03-11 Shin Etsu Chem Co Ltd Enteric coating composition
DE2923279C2 (de) 1979-06-08 1987-07-09 Kali-Chemie Pharma Gmbh, 3000 Hannover Verfahren zur Herstellung von Pankreatin-Pellets und diese enthaltende Arzneimittel
JPS5885159A (ja) 1981-11-17 1983-05-21 Furointo Sangyo Kk 溶出試験装置
EP0115023B1 (de) 1982-12-30 1988-07-27 Nordmark Arzneimittel GmbH Verfahren zur Gewinnung von Pankreatin
US4447412A (en) 1983-02-01 1984-05-08 Bilton Gerald L Enzyme-containing digestive aid compostions
US4704295A (en) 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
DE3445301A1 (de) 1984-12-12 1986-06-12 Hoechst Ag, 6230 Frankfurt Pankreasenzympraeparate und verfahren zu deren herstellung
DE3689727T2 (de) 1985-12-27 1994-07-07 Showa Denko Kk Granulierungsverfahren für enzyme.
US4849227A (en) 1986-03-21 1989-07-18 Eurasiam Laboratories, Inc. Pharmaceutical compositions
HU207452B (en) 1986-03-21 1993-04-28 Eurasiam Lab Method for producing therapeutical preparations containing active ingredient having biologicallu active protein structure
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
FR2603804B1 (fr) 1986-09-17 1989-10-27 Jouveinal Sa Lipases et extraits lipasiques, leur procede de preparation et leur application en therapeutique
IT1205716B (it) 1987-01-21 1989-03-31 Samil Spa Procedimento per la preparazione di microsfere gastroresistenti ed enterosolubili di enzima digestivo e preparato faramceutico a microsfere cosi' prodotto
DK435687D0 (da) † 1987-08-21 1987-08-21 Novo Industri As Enzymholdigt granulat og fremgangsmaade til fremstilling deraf
US5733763A (en) † 1988-08-19 1998-03-31 Novo Nordisk A/S Enzyme granulate formed of an enzyme-containing core and an enzyme-containing shell
DK78089D0 (da) † 1989-02-20 1989-02-20 Novo Industri As Detergentholdigt granulat og fremgangsmaade til fremstilling deraf
DK78189D0 (da) † 1989-02-20 1989-02-20 Novo Industri As Enzymholdigt granulat og fremgangsmaade til fremstilling deraf
DK306289D0 (da) † 1989-06-21 1989-06-21 Novo Nordisk As Detergentadditiv i granulatform
DE3927286C2 (de) 1989-08-18 1997-07-24 Roehm Gmbh Wäßrige Enzym-Flüssigformulierungen
CA2030581C (en) 1989-11-24 2000-06-27 Gunther Atzl Pancreatin preparations
IT1246350B (it) 1990-07-11 1994-11-17 Eurand Int Metodo per ottenere una rapida sospensione in acqua di farmaci insolubili
JPH0790565B2 (ja) 1991-08-06 1995-10-04 株式会社日本製鋼所 樹脂成形プレスのスライド制御方法及びその装置
US5225202A (en) 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
WO1993007859A1 (en) 1991-10-23 1993-04-29 Warner-Lambert Company Novel pharmaceutical pellets and process for their production
SE9200858L (sv) 1992-03-20 1993-09-21 Kabi Pharmacia Ab Metod för framställning av pellets med fördröjd frisättning
US5616483A (en) 1992-06-11 1997-04-01 Aktiebolaget Astra Genomic DNA sequences encoding human BSSL/CEL
US5578304A (en) 1992-06-22 1996-11-26 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5460812A (en) † 1992-06-22 1995-10-24 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5260074A (en) 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5308832A (en) 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury
DE4227385A1 (de) 1992-08-19 1994-02-24 Kali Chemie Pharma Gmbh Pankreatinmikropellets
JP3264027B2 (ja) 1993-02-24 2002-03-11 ソニー株式会社 放電セル及びその製造方法
US5955448A (en) 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
RU94017352A (ru) 1994-05-11 1996-07-27 Товарищество с ограниченной ответственностью "Инвест" Способ лечения онкологических больных, перенесших операцию на желудочно-кишечном тракте
DE4422433A1 (de) † 1994-06-28 1996-01-04 Cognis Bio Umwelt Mehrenzymgranulat
JPH10503739A (ja) 1994-08-05 1998-04-07 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 感湿性物質用容器
US5733575A (en) 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
EP0828509B1 (en) 1995-05-31 2005-01-26 Medzyme N.V. Composition to improve digestibility and utilisation of nutrients
US6057139A (en) * 1995-06-29 2000-05-02 Mcneil-Ppc, Inc. Preblend of microcrystalline cellulose and lactase for making tablets
US5665428A (en) 1995-10-25 1997-09-09 Macromed, Inc. Preparation of peptide containing biodegradable microspheres by melt process
US5750104A (en) † 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
DE19622131A1 (de) † 1996-06-01 1997-12-04 Solvay Enzymes Gmbh & Co Kg Neue Enzymgranulate
EP0938657A4 (en) 1996-06-04 1999-10-27 Euro Celtique Sa IMPROVEMENTS OF DETECTION SYSTEMS AND METHOD FOR PREDICTING THE RESOLUTION CURVE OF A MEDICINE OF A PHARMACEUTICAL DOSAGE FORM
JPH1023888A (ja) 1996-07-10 1998-01-27 Kao Corp 酵素造粒物の製造方法
DE19724845A1 (de) 1996-08-28 1998-03-05 Solvay Pharm Gmbh Verwendung von komplexen Lipiden als stabilisierende Zusätze zu pharmazeutischen Zubereitungen von Verdauungsenzymgemischen
US8828432B2 (en) 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
GB9623205D0 (en) 1996-11-07 1997-01-08 Eurand Int Novel pharmaceutical compositions
CA2198317C (en) 1997-02-24 2003-01-07 Mouhsine El Abboudi Method for preparing pancreatin which contains low amounts of residual organic solvent and product thereof
JPH10295374A (ja) 1997-04-30 1998-11-10 Amano Pharmaceut Co Ltd 安定な酵素顆粒の製造法
DE19721467A1 (de) 1997-05-22 1998-11-26 Basf Ag Verfahren zur Herstellung kleinteiliger Zubereitungen biologisch aktiver Stoffe
SE9702338D0 (sv) 1997-06-18 1997-06-18 Astra Ab An analytical method and industrial process including the same
ES2137862B1 (es) 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
JP3611456B2 (ja) 1997-09-30 2005-01-19 日研化学株式会社 テオフィリン徐放性錠剤
KR19990072826A (ko) 1998-02-26 1999-09-27 우재영 판크레아틴장용코팅과립의제조방법
US7201923B1 (en) 1998-03-23 2007-04-10 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
JPH11315043A (ja) 1998-04-30 1999-11-16 Lion Corp ヒドロキシエーテル化合物の製造方法及び洗浄剤組成物
US7122207B2 (en) 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
US20010024660A1 (en) 1999-09-29 2001-09-27 Ismat Ullah Enteric coated pharmaceutical composition and method of manufacturing
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
WO2000025752A1 (en) 1998-11-02 2000-05-11 Church, Marla, J. Multiparticulate modified release composition
ATE376057T1 (de) 1999-10-01 2007-11-15 Novozymes As Enzymgranulat
US20010046493A1 (en) 2000-02-24 2001-11-29 Alex Margolin Lipase-containing composition and methods of use thereof
AU2001254730A1 (en) 2000-03-24 2001-10-03 Societe Des Produits Nestle S.A. Nutritional composition comprising hydrolysed protein
AU2001244093A1 (en) 2000-04-03 2001-10-15 Novozymes A/S Enzyme tablets for cleaning improvement
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
AR032392A1 (es) 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.
AUPR272901A0 (en) 2001-01-25 2001-02-22 Gainful Plan Limited Method of preparing biological materials and preparations produced using same
DE60124895D1 (de) 2001-07-26 2007-01-11 Ethypharm Sa Umgehüllte Allylamine oder Benzylamine enthaltende Granulate, Verfahren zur Herstellung und in der Mundhöhle dispergierbare Tabletten enthaltend die umgehüllten Granulate
JP4187085B2 (ja) 2001-08-24 2008-11-26 三菱電機株式会社 車両用乗員保護装置
US20040197321A1 (en) * 2002-03-19 2004-10-07 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
CN1156308C (zh) 2002-04-19 2004-07-07 北京世诺医药科技有限公司 多酶组合胶囊
US20040121010A1 (en) 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
WO2004049820A1 (ja) * 2002-11-29 2004-06-17 Freund Corporation 水性セラック皮膜剤、その製造方法、該皮膜剤を用いたコーテッド食品、その製造方法、コーテッド医薬品、その製造方法、油性菓子の艶付用組成物、艶付方法、及び艶付油性菓子
CA2419572A1 (en) 2003-02-18 2004-08-18 Axcan Pharma Inc. High dosage protease formulation
US20040213847A1 (en) 2003-04-23 2004-10-28 Matharu Amol Singh Delayed release pharmaceutical compositions containing proton pump inhibitors
WO2005042012A1 (en) 2003-10-29 2005-05-12 Altus Pharmaceuticals Inc. Non-pancreatic proteases for controlling plasma cholecystokinin (cck) concentration and for treating pain
US7670624B2 (en) 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
PT1729797E (pt) 2004-03-22 2008-12-17 Solvay Pharm Gmbh Composições farmacêuticas orais de produtos contendo lipase, em particular de pancreatina, contendo tensioactivos
US20050281876A1 (en) 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US20060013807A1 (en) * 2004-07-13 2006-01-19 Chapello William J Rapidly disintegrating enzyme-containing solid oral dosage compositions
US20060198838A1 (en) 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
CN101068565B (zh) 2004-10-14 2010-11-17 胞囊纤维化基础治疗公司 治疗胰腺功能不全的包含脂酶、蛋白酶和淀粉酶的组合物
CN1247106C (zh) * 2004-11-01 2006-03-29 广东溢多利生物科技股份有限公司 多色微丸型饲用复合酶及其制造方法
JP4891549B2 (ja) 2005-01-19 2012-03-07 富士フイルム株式会社 プラスチック成形用金型
US20070025977A1 (en) † 2005-07-21 2007-02-01 Mulberg Andrew E Method of treating steatorrhea in infants
KR101199196B1 (ko) 2005-07-25 2012-11-07 (주)다산메디켐 구형의 판크레아틴 과립의 제조방법
AU2006274835B2 (en) 2005-07-29 2012-05-24 Abbott Laboratories Gmbh Processes for the manufacture of sterilized pancreatin powder
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
ATE457719T2 (de) 2005-08-15 2010-03-15 Solvay Pharm Gmbh Pharmazeutische zusammensetzungen mit kontrollierter freisetzung für säurelabile arzneimittel
JP5284092B2 (ja) 2005-08-15 2013-09-11 アボット ラボラトリーズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 腸溶コーティングに適したパンクレアチンマイクロペレットコア
WO2007053619A2 (en) 2005-11-01 2007-05-10 Bio-Cat, Inc. A composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency
US20070141151A1 (en) 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
JP5053865B2 (ja) † 2005-12-28 2012-10-24 武田薬品工業株式会社 口腔内崩壊性固形製剤の製造法
SG169334A1 (en) 2006-01-21 2011-03-30 Abbott Gmbh & Co Kg Dosage form and method for the delivery of drugs of abuse
JP2009538342A (ja) 2006-05-26 2009-11-05 ネステク ソシエテ アノニム トウチ抽出物の使用方法及び栄養組成物
EP2051591B1 (en) 2006-08-07 2016-04-20 Novozymes A/S Enzyme granules for animal feed
KR100804096B1 (ko) † 2006-08-31 2008-02-18 (주)아모레퍼시픽 고농도 계면활성제 계에서도 안정한 효소 캡슐 제제를포함하는 피부 세정용 조성물 및 그 제조방법
US9011843B2 (en) * 2006-12-14 2015-04-21 Master Supplements, Inc. Formulations including monovalent alginate to enhance effectiveness of administered digestive enzymes
US8066986B2 (en) 2007-02-01 2011-11-29 Master Supplements, Inc. Formulations including digestive enzymes and polysorbate surfactants that enhance the colonization of administered probiotics microoganisms
US20080199448A1 (en) 2007-02-16 2008-08-21 Ross Mairi R Enzyme composition for improving food digestion
RU2445952C2 (ru) 2007-02-20 2012-03-27 Юранд Фармасьютикалз Лимитед Стабильные композиции пищеварительных ферментов
SG186648A1 (en) 2007-02-20 2013-01-30 Aptalis Pharma Ltd Stable digestive enzyme compositions
US20090117180A1 (en) † 2007-02-20 2009-05-07 Giovanni Ortenzi Stable digestive enzyme compositions
AU2008239737A1 (en) 2007-04-13 2008-10-23 Beth Israel Deaconess Medical Center, Inc. Novel nutritional food products for improved digestion and intestinal absorption
CN101440361A (zh) * 2007-11-22 2009-05-27 珠海百康生物技术有限公司 一种制备稳定的包被颗粒酶的方法
KR20100101106A (ko) 2008-01-03 2010-09-16 애보트 프러덕츠 게엠베하 정제 미생물 리파제 과립들을 포함하는 약학 조성물 및 소화 장애들의 예방 또는 치료방법
CN101249081A (zh) 2008-02-15 2008-08-27 南京大渊美容保健有限公司 口服控释给药药片
US10087493B2 (en) 2008-03-07 2018-10-02 Aptalis Pharma Canada Ulc Method for detecting infectious parvovirus in pharmaceutical preparations
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
EP2328609A1 (en) 2008-08-26 2011-06-08 Cystic Fibrosis Foundation Therapeutics, Inc. Rapidly disintegrating tablets comprising lipase, amylase, and protease
CN101430279A (zh) 2008-10-27 2009-05-13 江南大学 荧光分光光度法筛选催化非水相体系转酯化反应用酶的方法
CN101623269A (zh) * 2009-08-04 2010-01-13 南京大渊美容保健有限公司 口服缓释给药的颗粒
US8784884B2 (en) 2009-09-17 2014-07-22 Stephen Perrett Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency
JP2011093845A (ja) 2009-10-29 2011-05-12 宏之 ▲今▼西 胃瘻用注入剤及びその注入装置
WO2011072069A2 (en) † 2009-12-08 2011-06-16 Depomed, Inc. Gastric retentive pharmaceutical compositions for extended release of polypeptides
RU2012142134A (ru) 2010-03-19 2014-04-27 Апталис Фарма Кэнэда Инк. Желудочно-резистентные ферментные фармацевтические композиции
JP5876472B2 (ja) 2010-04-14 2016-03-02 ダウ グローバル テクノロジーズ エルエルシー フロス及び非フロスコーティング用の分配装置
GB201006178D0 (en) 2010-04-14 2010-06-02 Ayanda As Composition
TW201210517A (en) 2010-08-06 2012-03-16 Aptalis Pharma Ltd Predigested nutritional formula
AR082943A1 (es) 2010-08-06 2013-01-23 Aptalis Pharma Ltd Formula nutricional predigerida
JP6043929B2 (ja) 2010-10-01 2016-12-14 アラガン ファーマシューティカルズ インターナショナル リミテッド 腸溶コーティングされた低力価パンクレリパーゼ製剤
TW201216951A (en) 2010-10-21 2012-05-01 Aptalis Pharma Ltd Oral dosing device for administration of medication
JP6166714B2 (ja) 2011-03-27 2017-07-19 セルレシン テクノロジーズ， エルエルシー シクロデキストリン組成物、物品、及び方法
EP2987499B1 (en) 2011-08-08 2019-05-08 Allergan Pharmaceuticals International Limited Method for dissolution testing of solid compositions containing digestive enzymes
CN103060296B (zh) 2012-12-30 2014-05-21 青岛九龙生物医药有限公司 从动物胰脏中提取胰蛋白酶的方法
AU2014229330B2 (en) 2013-03-15 2018-08-09 Allergan Pharmaceuticals International Limited Composition containing digestive enzymes and nutrients suitable for enteral administration
US10184121B2 (en) 2013-06-28 2019-01-22 Allergan Pharmaceuticals International Limited Methods for removing viral contaminants from pancreatic extracts
MX2016000794A (es) 2013-07-22 2016-12-02 Allergan Pharmaceuticals Int Ltd Composiciones farmaceuticas de pancreatina de potencia alta.
JP2016537387A (ja) 2013-08-09 2016-12-01 アラガン ファーマシューティカルズ インターナショナル リミテッド 経腸投与に適した消化酵素組成物
CN106659773A (zh) 2013-11-05 2017-05-10 阿勒根制药国际有限公司 高效的胰酶药物组合物
EP3035780A1 (de) 2014-12-18 2016-06-22 Siemens Aktiengesellschaft Kühlkörper
CN204811577U (zh) † 2015-07-09 2015-12-02 佛山市南海中宇渔具有限公司 渔轮及其线壳

Also Published As

Publication number Publication date
AU2011309763A1 (en) 2013-04-18
AU2015243026A1 (en) 2015-11-05
EA029101B1 (ru) 2018-02-28
SA111320804B1 (ar) 2014-11-05
JP6043929B2 (ja) 2016-12-14
IL225504A0 (en) 2013-06-27
EA201590836A1 (ru) 2015-11-30
EP2621476B1 (en) 2014-07-30
US20220280433A1 (en) 2022-09-08
EP2621476B8 (en) 2020-12-23
AU2011309763B2 (en) 2015-08-13
CL2011002432A1 (es) 2012-04-20
KR101968457B1 (ko) 2019-04-11
BR112013007640A2 (pt) 2017-09-26
EP2621476A1 (en) 2013-08-07
KR20180088742A (ko) 2018-08-06
CN103221036A (zh) 2013-07-24
ES2657673T3 (es) 2018-03-06
AU2015243026B2 (en) 2017-05-25
DK2621476T4 (da) 2020-10-26
UA111726C2 (uk) 2016-06-10
EP2818160A1 (en) 2014-12-31
EA201390409A1 (ru) 2013-11-29
IL225504A (en) 2017-02-28
EA030450B1 (ru) 2018-08-31
JP2013538846A (ja) 2013-10-17
MX2013003627A (es) 2013-12-02
PL2621476T3 (pl) 2015-01-30
ZA201303087B (en) 2014-07-30
HRP20140995T1 (hr) 2015-01-02
JP2017031203A (ja) 2017-02-09
SMT201400149B (it) 2015-01-15
EP2621476B2 (en) 2020-07-22
WO2012042372A1 (en) 2012-04-05
KR20140019292A (ko) 2014-02-14
RS53587B1 (en) 2015-02-27
ES2515715T5 (es) 2021-06-22
CO6700848A2 (es) 2013-06-28
CA2812862C (en) 2018-11-20
PL2621476T5 (pl) 2022-06-06
EA030449B1 (ru) 2018-08-31
CA2812862A1 (en) 2012-04-05
US11364205B2 (en) 2022-06-21
DK2621476T3 (da) 2014-10-27
CN108187033A (zh) 2018-06-22
EP2818160B1 (en) 2017-11-08
AR093181A1 (es) 2015-05-27
US20120201875A1 (en) 2012-08-09
JP6383394B2 (ja) 2018-08-29
PT2621476E (pt) 2014-10-16
EA201590835A1 (ru) 2015-11-30
SI2621476T1 (sl) 2014-12-31
MX348118B (es) 2017-05-26

Similar Documents

Publication Publication Date Title
ES2515715T3 (es) Formulaciones de pancreolipasa de baja potencia con recubrimiento entérico
JP6937086B2 (ja) ブルトン型チロシンキナーゼ阻害剤の結晶形態
AU2010231701B2 (en) Orally disintegrating coated tablet
JP6220485B2 (ja) コロイドビスマスペクチンを含有する分散製剤及びその製造方法
US20220218602A1 (en) Oral pharmaceutical composition
JP2017523206A (ja) ブルトン型チロシンキナーゼ阻害剤の新規製剤
RU2600831C2 (ru) Перорально вводимая фармацевтическая композиция
WO2006123678A1 (ja) ドロキシドパを含有する安定な錠剤
KR20200058496A (ko) 니라파립 제제
US10881610B2 (en) Orally disintegrating tablet
CN109843269A (zh) 来那度胺的口服用片剂组合物
JP2012508230A (ja) ロスバスタチンカルシウム組成物の取得方法及び得られた産物
JP2007153887A (ja) アンブロキソール口腔内速崩性錠剤
CN101330919B (zh) 包含(e)-7-[4-(4-氟苯基)-6-异丙基-2-[甲基(甲磺酰基)氨基]嘧啶-5-基]-(3r,5s)-3,5-二羟基庚-6-烯酸的药物组合物
WO2014157264A1 (ja) 口腔内崩壊性フィルムコーティング錠
CN103282051A (zh) 口腔内崩解片剂
CN102106809B (zh) 一种氯吡格雷的固体制剂及其制备方法
ES2949817T3 (es) Composición farmacéutica que contiene tosilato de sorafenib cristalino
JP5822758B2 (ja) 速溶性防湿フィルムコーティング製剤及びその製造方法
CN105534929A (zh) 曲格列汀药物组合物
CN108159053A (zh) 一种含有头孢妥仑匹酯的药物组合物
JP6676816B1 (ja) Ｌ−システイン配合ビタミンｃ高含有圧縮成形製剤
JPWO2014188729A1 (ja) 経口用組成物
CN109200020A (zh) 一种埃索美拉唑镁的药物组合物
Udaya Kiran et al. Annals of Drug discovery and Biomedical Research